Japan Familial adenomatous polyposis prevention study: Randomized controlled trial by low-dose aspiri
- Conditions
- Familial adenomatous polyposis
- Registration Number
- JPRN-UMIN000000698
- Lead Sponsor
- Basic and clinical researches on the development of chemopreventive drugs
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Not provided
# Patients currently taking antithrombotics such as Bayaspirin, Bufferin, Panaldine, Warfarin and Persantin # Patients with gastric ulcer, small intestinal ulcer, anastomotic ulcer or colorectal ulcer # Patients with a history of treatment of gastric or duodenal ulcer (those with successful eradication of Helicobacter pylori and ulcer resolution at S2 are allowed to participate in the study) # Confirmation method Each candidate patient should be interviewed to confirm that he or she has no medical history of gastric or duodenal ulcer and no pain in fasting state. Most recent GIF or UGI findings should be obtained as much as possible. # Patients with bleeding tendency, a platelet count of < 100,000, or with abnormal PT # Patients with any existing cancer at the time of participation in the study. # Patients with known allergy to aspirin. # Patients currently taking anticancer drugs. # Women who are or may be pregnant during the study period. # Patients currently taking NSAIDs at least 3 times weekly, for example, as a analgesic.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Only a reduction in the number of rectal tumors is regarded as the event.
- Secondary Outcome Measures
Name Time Method